2004 Fiscal Year Final Research Report Summary
Prediction of hormone refractory recurrence of prostate cancer by androgen receptor specific coactivator p120β
| Project/Area Number |
14370502
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Dokkyo University, School of Medicine (2004)
Gunma University (2002-2003) |
|---|
Principal Investigator |
FUKABORI Yoshitatsu Dokkyo University, School of Medicine Department of Urology, Associate Professor, 医学部, 助教授 (90199167)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MONDEN Tsuyoshi Dokkyo University, School of Medicine Department of Medicine, Assistant Professor, 医学部, 講師 (20323363)
OYAMA Tetsunari Gunma University, School of Medicine Department of Pathology, Associate Professor, 医学部, 助教授 (50233622)
SHIBATA Yasuhiro Gunma University, School of Medicine Department of Urology, Research Associate, 医学部, 助手 (90344936)
|
|---|
| Project Period (FY) |
2002 – 2004
|
| Keywords | androgen / receptor / coactivator / nuclear receptor / prostate / hormone refractory / recurrence / prediction |
|---|
| Research Abstract |
We tested ability reference about real time quantitative PCR device of Applied Biosystems company and BioRad company. We decided to purchase iCycler of BioRad company that allowed us to assay from a low concentration of p120β only with conventional TaqMan Probe. We confirmed that we could assay GAPDH, p120α and p120β to low concentration of 50 copies using iCycler iQ system.
There was no significance of p120α expression among the group of BPH (group of B), newly diagnosed prostate cancer (group of N) and locally relapsing prostate cancer (group of R). There was a significant difference of p120β expression among the group of B,N and R. The expression of p120β decreased in order of a group of B, a group of N, a group of R.
We evaluated the value of p120α and p120β expression pattern in prostate biopsy specimen as a predictor of early biochemical failure in advanced prostate cancer treated with androgen ablation therapy. Newly diagnosed 49 patients with advanced prostate cancer were treated with androgen ablation therapy and were prospectively investigated by Kaplan-Meier method. End-point of this study was PSA biochemical failure (PSA-BF). The significant differential of PSA-BF was not found between p120β high level expression group and p120β low expression group. There was a significant difference of PSA-BF rate between p120α high level expression group and low expression group. The probability that p120α was a new molecular marker which predicts PSA-BF was shown in hormone therapy of prostatic cancer.
|
Research Products
(9 results)
